Payment overview · 2025
General Payments
$427.69
24 reported records · 12 companies
Healthcare provider profile · identity verified
Ross Lenzen
Allopathic & Osteopathic Physicians|Family Medicine · GREENBRIER, AR · NPI 1497376453
Verified facts
What the public records show
CMS Open Payments records show Ross Lenzen received $427.69 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.02 | 26.9% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.73 | 17.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.63 | 9.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.10 | 8.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.45 | 7.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.05 | 6.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.78 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.47 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.55 | 3.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.46 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.25 | 3.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.20 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.69 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.02 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 109 |
| Gabapentin | Gabapentin | 395 | 109 |
| Metformin Hcl | Metformin Hcl | 350 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 93 |
| Omeprazole | Omeprazole | 297 | 90 |
| Losartan Potassium | Losartan Potassium | 272 | 79 |
| Lisinopril | Lisinopril | 261 | 79 |
| Tramadol Hcl | Tramadol Hcl | 201 | 50 |
| Trazodone Hcl | Trazodone Hcl | 196 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 55 |
| Ozempic | Semaglutide | 163 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 67 |
| Furosemide | Furosemide | 155 | 48 |
| Atenolol | Atenolol | 152 | 34 |
| Sertraline Hcl | Sertraline Hcl | 146 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 63 |
| Simvastatin | Simvastatin | 141 | 38 |
| Potassium Chloride | Potassium Chloride | 138 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 33 |
| Prednisone | Prednisone | 128 | 83 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 119 | 97 |
| Carvedilol | Carvedilol | 110 | 35 |
| Allopurinol | Allopurinol | 106 | 22 |
| Buspirone Hcl | Buspirone Hcl | 95 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 18 |
| Ondansetron Odt | Ondansetron | 91 | 40 |
| Glipizide | Glipizide | 90 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Meloxicam | Meloxicam | 87 | 31 |
| Eliquis | Apixaban | 86 | 21 |
| Alprazolam | Alprazolam | 85 | 16 |
| Famotidine | Famotidine | 85 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 24 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Bupropion Xl | Bupropion Hcl | 75 | 25 |
| Baclofen | Baclofen | 68 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 29 |
| Ezetimibe | Ezetimibe | 66 | 23 |
| Clonazepam | Clonazepam | 63 | 15 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 15 |
| Aripiprazole | Aripiprazole | 58 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 14 |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Fluconazole | Fluconazole | 42 | 29 |
| Spironolactone | Spironolactone | 42 | 13 |
| Sucralfate | Sucralfate | 42 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 37 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 11 |
| Benazepril Hcl | Benazepril Hcl | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 39 | 14 |
| Nystatin | Nystatin | 39 | 20 |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 32 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Nifedipine Er | Nifedipine | 32 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Ofloxacin | Ofloxacin | 25 | 21 |
| Hydrocortisone | Hydrocortisone | 24 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Valsartan | Valsartan | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Wegovy | Semaglutide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $427.69 · 24 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, KEVEYIS, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error